A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

Nidhi Gupta, Niels Fisker, Marie-Claude Asselin, Marie Lindholm, Christoph Rosenbohm, Henrik Ørum, Joacim Elmén, Nabil G Seidah, Ellen Marie Straarup

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important factor in the etiology of familial hypercholesterolemia (FH) and is also an attractive therapeutic target to reduce low density lipoprotein (LDL) cholesterol. PCSK9 accelerates the degradation of hepatic low density lipoprotein receptor (LDLR) and low levels of hepatic PCSK9 activity are associated with reduced levels of circulating LDL-cholesterol.
Original languageEnglish
Article numbere10682
JournalPLOS ONE
Volume5
Issue number5
ISSN1932-6203
DOIs
Publication statusPublished - 2010
Externally publishedYes

Keywords

  • Animals
  • Cell Death
  • Cell Membrane
  • Cell Survival
  • Flow Cytometry
  • Gene Silencing
  • Hep G2 Cells
  • Humans
  • Injections, Intravenous
  • Intracellular Space
  • Mice
  • Oligonucleotides
  • Oligonucleotides, Antisense
  • Polymerase Chain Reaction
  • Proprotein Convertases
  • RNA, Messenger
  • Receptors, LDL
  • Serine Endopeptidases

Fingerprint

Dive into the research topics of 'A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo'. Together they form a unique fingerprint.

Cite this